Author: admin

  • Dell Technologies Strategy Remains Steady Despite CFO Departure, Say Analysts

    Dell Technologies Strategy Remains Steady Despite CFO Departure, Say Analysts

    Dell Technologies (NASDAQ:DELL) announced the departure of Chief Financial Officer Yvonne McGill, effective September 9, 2025, just weeks ahead of its highly anticipated Strategic Analyst Meeting (SAM).

    McGill’s tenure, roughly two years, was shorter than most of her predecessors, who typically served five to ten years in the role.

    The company has appointed David Kennedy, a 27-year Dell veteran and current COO of Global Sales, as interim CFO while it conducts a search for a permanent replacement, considering both internal and external candidates.

    Also Read: Dell Struggles To Protect Margins As Supply Chain Costs Mount

    Investors may interpret the timing of the CFO transition as a potential signal of strategic change. However, JPMorgan analysts led by Samik Chatterjee suggest that the move is unlikely to affect Dell’s near-term financial outlook.

    Investors should largely view the strategy as unchanged in terms of AI revenue growth, profitability, and expense management, the team said, noting that Dell’s core financial strategy remains consistent regardless of its overall revenue trajectory.

    Instead, the CFO change may reflect the board and management’s confidence in the company’s ability to create shareholder value.

    JPMorgan maintains an Overweight rating on Dell with a $145 price forecast, underscoring the stability of its financial and strategic trajectory.

    Dell has made notable progress in establishing leadership in AI servers, recovering from an initially slow start, and has managed tariffs with limited financial impact.

    Analysts expect that these accomplishments, along with ongoing operational execution, could be more prominently highlighted at the upcoming SAM.

    David Kennedy brings extensive experience to the interim role, including serving as Senior Vice President and CFO of Dell’s Client Solutions Group (CSG).

    His appointment ensures continuity while Dell evaluates permanent candidates, in contrast with previous transitions that relied solely on internal promotions.

    While the CFO change has prompted speculation, JPMorgan analysts maintain an Overweight rating on Dell, emphasizing that the company’s financial and strategic trajectory remains stable.

    They anticipate that the SAM will likely place greater emphasis on value creation for shareholders, underscoring Dell’s executional strength and market positioning in key growth areas such as AI infrastructure.

    Price Action: Dell stock is trading lower by 1.87% to $120.72 at last check Tuesday.

    Read Next:

    Continue Reading

  • IFITM3 found to be critical regulator of immunotherapy sensitivity in small cell lung cancer

    IFITM3 found to be critical regulator of immunotherapy sensitivity in small cell lung cancer

    New research presented identifies interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade.

    The research was presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).

    SCLC tumors are typically characterized by low expression of major histocompatibility complex class I (MHC-I), which impairs immune recognition and response. Researchers from the Shanghai Pulmonary Hospital and the University of Pittsburgh have discovered that IFITM3 enhances MHC-I expression by activating NLRC5, a key transcriptional regulator, and promoting its nuclear translocation. This effect improves antigen presentation and boosts CD8⁺ T cell infiltration and cytotoxicity.

    Our study shows that IFITM3 plays a pivotal role in shaping tumor immunogenicity in SCLC. It may serve both as a predictive biomarker for immunotherapy response and a novel therapeutic target.”


    Dr. Xinyu Liu of Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

    Dr. Liu presented a number of significant findings:

    • Strong correlation between IFITM3 and MHC-I expression in multiple real-world SCLC cohorts.

    • IFITM3 overexpression upregulated antigen presentation pathways and increased CD8⁺ T cell infiltration.

    • IFITM3 expression predicted improved progression-free survival in patients receiving chemoimmunotherapy.

    • A novel compound, ethyl gallate (EG), induced IFITM3 and sensitized tumors to PD-1 blockade in preclinical models.

    “Our study suggests that pharmacological induction of IFITM3 could represent a new strategy to improve clinical outcomes for patients with SCLC. Future clinical research may validate IFITM3 as both a biomarker and a therapeutic adjunct to current immunotherapy regimens,” Dr. Liu reported.

    Source:

    International Association for the Study of Lung Cancer

    Continue Reading

  • Four teams on track in Monza with Pirelli to test 2026 compounds

    Four teams on track in Monza with Pirelli to test 2026 compounds

    Four teams were on track today at Monza for the first of two days of testing organised by Pirelli to work on 2026 tyre development. Having won the Italian Grand Prix here on Sunday, Max Verstappen was back in action along with Red Bull Racing team-mate Yuki Tsunoda, Aston Martin’s reserve driver Felipe Drugovich, Williams’ Carlos Sainz and Racing Bulls’ Isack Hadjar.

    The original plan for today was that Red Bull would be on track with Verstappen in the morning and Tsunoda in the afternoon, joined by Drugovich in the Aston Martin. However, with storms and heavy rain forecast for tomorrow morning, the schedule was changed.

    After the morning session, Williams and Racing Bulls were ready to get through part of their programme ahead of schedule, running Sainz and Hadjar this afternoon. Aston Martin and Williams ran modified versions of their current cars, the AMR25 and FW47 respectively, adapted to accept the prototype tyres. Red Bull used a mule car based on the 2023 RB19 and Racing Bulls did the same with a VCARB01 from 2024.

    The overall programme for this test is focussed on finalising what slick compounds to use for next season. In fact, the tyre construction was homologated on 1st September, as per the regulations. The test in Monza is the seventh session organised by Pirelli so far this year to develop the new tyres which, while sticking with an 18 inch diameter are slightly narrower, by 25 mm at the front and 30 mm at the rear. 

    In the morning, the reigning world champion got through his programme, doing 59 laps before handing over to Tsunoda, who did 63 in the afternoon. Verstappen’s best time was a 1’24”117, set on his 25th lap, while the Japanese driver posted a 1’23’’826 on his 30th lap. In the Aston Martin, Drugovich completed 118 laps over the course of the day, with a best time of 1’23”792 set on lap 37.

    Carlos Sainz did 49 laps in the Williams with a best time of 1’22’’388 set on lap 30. Isack Hadjar completed 65 laps, his best being a 1’23’’951 set on lap 41. The times have no comparative value as they are linked to the specific programme assigned to each driver.

    All teams tried the softest compounds in the range. Racing Bulls and Williams ran the C4, C5 and C6, while Red Bull Racing and Aston Martin also tried the C3. The programme began with quick lap runs to see the pure performance levels of the various compounds, before switching to longer runs to check the level of degradation. Ambient temperature ranged from 22°C and 27°C while the track varied between 24°C and 40°C.

    Inevitably, tomorrow’s programme will depend on the weather. If it only rains in the morning then the slick tyre testing will resume in the afternoon, with just Racing Bulls and Williams on track. If the rain continues into the afternoon, but not too heavily, then Pirelli might take the opportunity to also test the Cinturato Full Wet and Intermediate tyres. That would produce some useful data relating to the crossover point between the different compounds.

    ';

    Continue Reading

  • Staying Active Can Slow Cognitive Decline in Parkinson’s Disease

    Staying Active Can Slow Cognitive Decline in Parkinson’s Disease


    gotooo/Shutterstock.com

    If you have Parkinson’s disease (PD) and are staying active, you’re likely doing yourself a big favor.

    A new study shows that regular physical activity can help slow cognitive decline in people with PD. The findings support the belief that staying active is a key intervention for patients—one that could delay the disease’s progression, alleviate motor symptoms, and improve patients’ quality of life, according to the study, published online Aug. 6 in Neurology®. 

    “Understanding the long-term effects of regular physical activity on cognitive function is crucial because cognitive decline is a prevalent and highly debilitating non-motor symptom in patients with PD,” writes lead author Patricia Diaz-Galvan, PhD, of Virgen del Rocío University Hospital/CSIC/University of Seville and the Neurodegenerative Diseases Research Area (CIBERNED) at the National Institute of Health Carlos III in Spain, and colleagues.

    Previous PD research closely linked cognitive impairment to the degeneration of gray matter in the brain, the researchers note. Studies also have shown an association between deficits in memory, executive function, and visuospatial abilities in patients with PD and a greater amount of thinning in two parts of the brain, the temporoparietal and superior frontal cortices.

    To see whether they could find an association between regular physical activity and a drop in gray matter neurodegeneration, the researchers used data from the Parkinson’s Progression Markers Initiative, an international study started over a decade ago by The Michael J. Fox Foundation, academic scientists, and industry partners. The study included 120 patients with early PD who had undergone a series of MRI scans and regular assessments of their physical activity. The participants had a mean age of 60.8 years, and 33 percent were women. The study also included 164 healthy controls.

    The researchers used the MRI scans to measure different parts of the brain and then analyzed the impact being physically active had on those measurements over time. They also looked at how changes to the brain’s structure affected the link between regular physical activity and cognitive function. Participants’ physical activity was measured using the Physical Activity Scale for the Elderly.

    The researchers found an association between regular physical activity and a slower rate of neurodegeneration in the brain’s temporoparietal cortex and limbic areas, regions they note contribute “to preserved cognitive function and improved long-term outcomes.” Specifically, the physical activity was associated with slower cortical thinning in several temporoparietal cortical regions as well as with slower volume loss in the hippocampus and the amygdala.

    “Our study linked brain changes to physical activity through multiple evaluations over time,” researchers say. 

    The findings “suggest that physical activity is essential for long-term neuroplasticity and should be part of a continuous PD management strategy,” researchers say. But further studies and clinical trials will be needed to test that theory as well as to see whether the changes that occurred in the brain from the physical activity last. 

    Ultimately, the researchers say, their findings “would help to shape future clinical trials and enhance current treatment guidelines for PD including physical activity as a key interventional factor.”


    Continue Reading

  • Vertebral Involvement in Pediatric Burkitt Lymphoma: A Case Report

    Vertebral Involvement in Pediatric Burkitt Lymphoma: A Case Report


    Continue Reading

  • Apple unveils Apple Watch Series 11, Watch Ultra 3, and Watch SE 3

    Apple unveils Apple Watch Series 11, Watch Ultra 3, and Watch SE 3

    Apple on Tuesday unveiled three new Apple Watch configurations and its annual hardware event: the Apple Watch Series 11, Apple Watch Ultra 3, and Apple Watch SE 3.

    Apple Watch Series 11

    The Apple Watch Series 11 can alert you to possible hypertension. It uses data from the optical heart sensor and looks for chronic high blood pressure by analyzing how your blood vessels respond to beats of the heart. The algorithm works in the background, reviewing data over 30-day periods and will notify you if it identifies patterns of hypertension.

    Apple says it plans to notify over 1 million people with undiagnosed hypertension in the first year alone.

    Image Credits:Apple

    The watch can also help you understand the quality of your sleep and how to make it more restorative. With the new Sleep Score, the quality of your sleep is influenced by several factors, such as sleep duration, bed time, consistency, how often you wake up, and the time spent in each sleep stage.

    It also debuts with 5G connectivity, bringing an improvement over the existing LTE connectivity options. It uses less battery and provides even more coverage.

    Apple Watch Series 11 now gets up to 24 hours of battery life and comes in Jet Black, Silver, Rose Gold and a new Space Gray. It starts at $399.

    Apple Watch Ultra 3

    The Apple Watch Ultra 3 is launching with a larger screen and satellite connectivity. As with the Series 11, it’s also getting 5G connectivity and hypertension notifications.

    Techcrunch event

    San Francisco
    |
    October 27-29, 2025

    The Apple Watch Ultra 3 is the first Apple Watch with satellite connectivity, allowing you to tap into Apple’s satellite feature for emergency communications in remote areas. You can also send messages and share your location with Find My to enable satellite connectivity.

    Satellite connectivity can be used in in times when a cellular signal or Wi-Fi is not available; it lets people do things like contact emergency services and send a text by satellite.

    The watch comes with up to 42 hours of battery life, with up to 72 hours in Low Power Mode.

    It comes with LTPO3 and wide-angle OLEDs, making it the largest screen of any Apple Watch ever, and brighter when viewed from an angle. TPO3 is a high-performance, low-power display technology that enables the display borders to be 24 percent thinner, Apple notes.

    Apple Watch Ultra 3 is available in Black and Natural Titanium. Prices start at $799.

    Apple Watch SE 3

    The Apple Watch SE 3 is launching with a newer display and a faster chip, the S10, which allows for a huge improvement over the S8 chip used in the Apple Watch SE 2.

    Image Credits:Apple

    The chip upgrade allows for always-on display for the first time. It also supports gestures like double-tap and wrist flick.

    The S10 chip also enables SE 3 to still get all day 18 hour battery life, and for the first time, the SE supports fast charging. The SE 3 comes with wrist temperature sensing, which enables retrospective ovulation estimates and gives you richer insights in the vitals app.

    Apple Watch SE starts at $249. It is available in 40mm and 44mm sizes in Midnight and Starlight aluminum cases.

    Continue Reading

  • Sri Lanka captain jokes about fatigue, focuses on staying fresh for Asia Cup opener

    Sri Lanka captain jokes about fatigue, focuses on staying fresh for Asia Cup opener

    Balaram brings more than two decades of experience in the media industry, combining sharp editorial judgment with a deep understanding of digital news dynamics.

    Since 2004, he has been a core member of the gulfnews.com digital team, playing a key role in shaping its identity.

    Passionate about current affairs, politics, cricket, entertainment, and viral content, Balaram thrives on stories that spark conversation. His strength lies in adapting to the fast-changing news landscape and curating compelling content that resonates with readers.

    Continue Reading

  • Canadian researchers 3D bioprint complex lung models | VoxelMatters

    Canadian researchers 3D bioprint complex lung models | VoxelMatters

    Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

    A team of researchers from the University of British Columbia (UBC) Okanagan campus have developed a 3D bioprinted lung tissue model that could have important applications in drug testing and research into lung disease. The bioprinted tissue structure, bioprinted using CELLINK’s LUMEN X DLP bioprinter, is made from a photopolymerizable bioink, itself consisting of 80% polyethylene glycol diacrylate (PEGDA) and 20% gelatin methacrylate (GelMa) (various cell types were embedded or seeded into the bioprinted structure).

    The importance of better understanding lung disease and developing more sophisticated treatments is critical, particularly in the context of UBC’s home country, where increasing wildfires are leading to significant decreases in air quality. Recent research suggests that this worsening air pollution could lead to Canadians’ life expectancy dropping by two years. For Dr. Emmanuel Osei, Assistant Professor in the Irving K. Barber Faculty of Science, and his team, this has been a consideration in their work.

    Their bioprinted lung model, which integrates vessels that closely mimic the structure of a real human lung, was exposed to cigarette smoke extract in one test, which enabled the researchers to study markers of inflammatory responses to the nicotine. “The fact that we’ve been able to create the model, then use particular triggers like cigarette smoke, to demonstrate how the model will react and mimic aspects of lung disease is a significant advancement in studying complex mechanisms of lung disease that will aid in studying how we treat them,” explained Dr. Osei.

    The bioprinted lung tissue will also play an important role in testing drugs for patients with lung cancer or other serious lung disease. Presently, the drug testing process involves a surgeon extracting a portion of cancerous tissue and healthy tissue from the patient and sending the samples to a research lab. The problem with this is that the sample size may not be big enough to test various treatments. With the ability to bioprint tissue, however, it could be possible to turn these samples into a more substantial model. “Now, with 3D bioprinting, we can isolate cells from these donated tissues and potentially recreate additional tissue and test samples to conduct research in our labs and not rely on or wait for contributed tissues,” Dr. Osei elaborated.

    The bioprinted lung research was recently published in the journal Biotechnology and Bioengineering and adds to a growing number of innovative bioprinting-based research initiatives targeting lung disease. In the past year alone, researchers from Tessella Biosciences (backed by Canada-based McMaster University) developed a bioink suitable for printing realistic lung models, and a project led by the US Department of Homeland Security’s Science and Technology Directorate pioneered the printing of lung tissue onto microchips to test the effects of toxic vapours like ammonia and chlorine.

    “Our goal was to create a more physiologically relevant in vitro model of the human airway,” said Dr. Osei. “By integrating vascular components, we can better simulate the lung environment, which is crucial for studying diseases and testing therapeutics. Our model is complex, but due to the reproducibility and optimal nature of bio-printing, it can be adapted to include additional cell types or patient-derived cells, making it a powerful tool for personalized medicine and disease modelling.”

    Continue Reading

  • Introducing Apple Watch Ultra 3

    Introducing Apple Watch Ultra 3

    Continue Reading

  • Downton Abbey: The Grand Finale Premieres in New York – Focus Features

    Downton Abbey: The Grand Finale Premieres in New York – Focus Features

    1. Downton Abbey: The Grand Finale Premieres in New York  Focus Features
    2. ‘Downton Abbey: The Grand Finale’ Review: The Beloved Franchise Bows Out on a Confident Parting Note  Variety
    3. Downton Abbey: The Magic of Maggie Smith.  FILMHOUNDS Magazine
    4. All Downton Abbey Movies and TV Seasons, Ranked by Tomatometer  Rotten Tomatoes
    5. Downton Abbey The Grand Finale Actor Alessandro Nivola On Sambrook’s Character Arc: He Arrives With Harold…  Times Now

    Continue Reading